Browsing by Author "Boskovic, Srdjan (57350047000)"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Differential expression and localization of Ankrd2 isoforms in human skeletal and cardiac muscles(2016) ;Jasnic-Savovic, Jovana (56394601600) ;Krause, Sabine (26221816900) ;Savic, Slobodan (7005859439) ;Kojic, Ana (57190162425) ;Kovcic, Vlado (23473632600) ;Boskovic, Srdjan (57350047000) ;Nestorovic, Aleksandra (30567467500) ;Rakicevic, Ljiljana (14047140100) ;Schreiber-Katz, Olivia (56575172800) ;Vogel, Johannes G. (56669255000) ;Schoser, Benedikt G. (7004885775) ;Walter, Maggie C. (7402841766) ;Valle, Giorgio (7102644197) ;Radojkovic, Dragica (6602844151) ;Faulkner, Georgine (7005753370)Kojic, Snezana (6602130666)Four human Ankrd2 transcripts, reported in the Ensembl database, code for distinct protein isoforms (360, 333, 327 and 300 aa), and so far, their existence, specific expression and localization patterns have not been studied in detail. Ankrd2 is preferentially expressed in the slow fibers of skeletal muscle. It is found in both the nuclei and the cytoplasm of skeletal muscle cells, and its localization is prone to change during differentiation and upon stress. Ankrd2 has also been detected in the heart, in ventricular cardiomyocytes and in the intercalated disks (ICDs). The main objective of this study was to distinguish between the Ankrd2 isoforms and to determine the contribution of each one to the general profile of Ankrd2 expression in striated muscles. We demonstrated that the known expression and localization pattern of Ankrd2 in striated muscle can be attributed to the isoform of 333 aa which is dominant in both tissues, while the designated cardiac and canonical isoform of 360 aa was less expressed in both tissues. The 360 aa isoform has a distinct nuclear localization in human skeletal muscle, as well as in primary myoblasts and myotubes. In contrast to the isoform of 333 aa, it was not preferentially expressed in slow fibers and not localized to the ICDs of human cardiomyocytes. Regulation of the expression of both isoforms is achieved at the transcriptional level. Our results set the stage for investigation of the specific functions and interactions of the Ankrd2 isoforms in healthy and diseased human striated muscles. © 2016, Springer-Verlag Berlin Heidelberg. - Some of the metrics are blocked by yourconsent settings
Publication Differential expression and localization of Ankrd2 isoforms in human skeletal and cardiac muscles(2016) ;Jasnic-Savovic, Jovana (56394601600) ;Krause, Sabine (26221816900) ;Savic, Slobodan (7005859439) ;Kojic, Ana (57190162425) ;Kovcic, Vlado (23473632600) ;Boskovic, Srdjan (57350047000) ;Nestorovic, Aleksandra (30567467500) ;Rakicevic, Ljiljana (14047140100) ;Schreiber-Katz, Olivia (56575172800) ;Vogel, Johannes G. (56669255000) ;Schoser, Benedikt G. (7004885775) ;Walter, Maggie C. (7402841766) ;Valle, Giorgio (7102644197) ;Radojkovic, Dragica (6602844151) ;Faulkner, Georgine (7005753370)Kojic, Snezana (6602130666)Four human Ankrd2 transcripts, reported in the Ensembl database, code for distinct protein isoforms (360, 333, 327 and 300 aa), and so far, their existence, specific expression and localization patterns have not been studied in detail. Ankrd2 is preferentially expressed in the slow fibers of skeletal muscle. It is found in both the nuclei and the cytoplasm of skeletal muscle cells, and its localization is prone to change during differentiation and upon stress. Ankrd2 has also been detected in the heart, in ventricular cardiomyocytes and in the intercalated disks (ICDs). The main objective of this study was to distinguish between the Ankrd2 isoforms and to determine the contribution of each one to the general profile of Ankrd2 expression in striated muscles. We demonstrated that the known expression and localization pattern of Ankrd2 in striated muscle can be attributed to the isoform of 333 aa which is dominant in both tissues, while the designated cardiac and canonical isoform of 360 aa was less expressed in both tissues. The 360 aa isoform has a distinct nuclear localization in human skeletal muscle, as well as in primary myoblasts and myotubes. In contrast to the isoform of 333 aa, it was not preferentially expressed in slow fibers and not localized to the ICDs of human cardiomyocytes. Regulation of the expression of both isoforms is achieved at the transcriptional level. Our results set the stage for investigation of the specific functions and interactions of the Ankrd2 isoforms in healthy and diseased human striated muscles. © 2016, Springer-Verlag Berlin Heidelberg. - Some of the metrics are blocked by yourconsent settings
Publication Neutrophil elastase gene polymorphisms: Modulators of response to therapy in childhood bronchiectasis?(2014) ;Nikolic, Aleksandra (57194842918) ;Milosevic, Katarina (6508374642) ;Boskovic, Srdjan (57350047000)Nestorovic, Branimir (6603001653)Background: The aim of this study was to investigate polymorphisms in the promoter region of the neutrophil elastase (ELANE) gene as potential modulators of the therapeutic response in children with idiopathic bronchiectasis. Methods: The study included 48 children between 5 and 17 years old who were diagnosed with idiopathic bronchiectasis based on high-resolution computed tomography of the thorax. In all patients therapy included administration of antibiotics, anti-inflammatory drugs, expectorants, and postural drainage. Response to therapy was evaluated by the change in FeNO levels before and after administration of therapy. The ELANE promoter region polymorphisms were analyzed by PCR-direct DNA sequencing. Results: According to the predicted activity of ELANE genotypes, subjects were divided into two groups: low/intermediate activity (n = 18) and high activity (n = 30). Subjects in the group with high-activity genotype had higher initial FeNO levels and this difference was statistically significant (t = 2.906; p = 0.006). The difference between FeNO levels before and after therapy was also statistically significantly higher in children with high-activity genotype (t = 3.329; p = 0.002). Statistically significant correlation was observed between the change in FeNO levels and ELANE genotypes (r = 0.350; p = 0.015). Conclusion: Children with high-activity genotype had higher initial FeNO levels and showed better response to therapy than children with low/intermediate-activity genotypes. © 2014 Springer Science+Business Media.
